Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

In collaboration with colleagues at the University of Nottingham, the Burton group in Pharmacology performed safety modelling with uncertainty quantification using a risk classifier based on the qNet torsade metric score, a measure of the net charge carried by major currents during the action potential under inhibition of multiple ion channels by a compound. Our simulation approach highlights that the torsadogenic potentials of hydorxychloqoruine (HCQ), chloroquine (CQ) and other QT-prolonging anti-infectives used in COVID-19 prevention and treatment increase with concentration and in combination with other QT-prolonging drugs.

https://royalsocietypublishing.org/doi/10.1098/rsos.210235

Similar stories

Modernized Oxford anti-arrhythmic drug classification gains global recognition as the new standard in antiarrhythmic drug clinical guidelines

Cardiac arrhythmias pose a serious global health challenge. The commonest sustained arrhythmia atrial fibrillation (AF) affects 1–2% of the worldwide population. Antiarrhythmic drugs (AADs) remain central to their pharmacotherapeutic management. As a solution, Professors Ming Lei, Derek Terrar (both Pharmacology), Christopher Huang (University of Cambridge), and Lin Wu (Beijing University Hospital) developed and proposed the 2018 Oxford modernized antiarrhythmic drug (AAD) classification (Circulation, 2018;138:1879–1896).